ALXO
ALX Oncology Holdings Inc.
8.98
USD
This page is just a preview of the data found in TrendSpider’s full version
ALX Oncology Holdings Inc. stock is up 30.52% since 30 days ago. The next earnings date is Mar 7, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 3 November’s closed higher than October. In the last 7 Unusual Options Trades, there were 4 PUTs, 3 CALLs. 100% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 03 Oct 19:54 | 20 Oct, 2023 | 7.50 | 0 | ||
| 10 Oct 19:59 | 17 Nov, 2023 | 10.00 | 1 | ||
| 16 Oct 14:06 | 17 May, 2024 | 5.00 | 150 | ||
| 17 Oct 19:40 | 17 Nov, 2023 | 7.50 | 534 | ||
| 19 Oct 16:31 | 20 Oct, 2023 | 7.50 | 1829 | ||
| 25 Oct 14:39 | 17 Nov, 2023 | 10.00 | 194 | ||
| 17 Nov 19:06 | 16 Feb, 2024 | 7.50 | 605 |
ALX Oncology Holdings Inc. focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial. ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer.
